Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289256 | 0.85 | L3MBTL1 (0.65) | ARGAASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL10576413 | 0.84 | SLC40A1 (0.59) | ARGAASMN1; SMN2L3MBTL1PGR | |
| SCHEMBL31235173 | 0.84 | AR (0.67) | ARGAASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL410747 | 0.84 | AR (0.67) | ARGAASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL5187428 | 0.83 | PGR (0.64) | GAASMN1; SMN2PKML3MBTL1PGR | |
| SCHEMBL15661006 | 0.83 | ALDH1A1 (0.61) | ARGAASMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL4282718 | 0.83 | AR (0.63) | ARGAASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL16680267 | 0.83 | SMN1; SMN2 (0.67) | ARGAASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL29589718 | 0.83 | AR (0.70) | ARGAASMN1; SMN2PKML3MBTL1 | |
| SCHEMBL95754 | 0.82 | GAA (0.66) | ARGAASMN1; SMN2PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1421057-A4 | CHEMOTHERAPEUTIC AGENTS | STARPHARMA PTY LTD (AU) | 2007-03-14 | — | — | EP | disclosed |
| EP-1668020-A2 | NOVEL ADENOSINE A SB 3 /SB RECEPTOR AGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005028489-A2 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050038248-A1 | Chemotherapeutic agents | STARPHARMA PTY LTD (AU) | 2005-02-17 | — | — | US | disclosed |
| EP-1421057-A1 | CHEMOTHERAPEUTIC AGENTS | Starpharma Limited (AU) | 2004-05-26 | — | — | EP | disclosed |
| US-20030232830-A1 | Non-covalent inhibitors of AmpC beta-lactamase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-18 | — | — | US | disclosed |
| WO-2003070682-A1 | NON-COVALENT INHIBITORS OF AmpC ß-LACTAMASE | NORTHWESTERN UNIVERSITY (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003018536-A1 | CHEMOTHERAPEUTIC AGENTS | STARPHARMA LIMITED (AU) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | AR 310/4885GAA 3857/4885SMN1; SMN2 3431/4885 |
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | AMPD1, AMPD2, AMPD3 | AR 3977/4885GAA 75/4885SMN1; SMN2 4668/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | AR 30/4885GAA 4207/4885SMN1; SMN2 2771/4885 |
| US-20030232830-A1 | Non-covalent inhibitors of AmpC beta-lactamase | AMPD1, AMPD3, AMPD2 | AR 4273/4885GAA 50/4885SMN1; SMN2 4650/4885 |
| US-20050038248-A1 | Chemotherapeutic agents | MKI67, PCNA, MCL1 | AR 3775/4885GAA 2267/4885SMN1; SMN2 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.